mAbsolve will be exhibiting at the Festival of Biologics in Basel on the 10-12th of October. We will be located in the startup zone will also have a poster with a more detailed description of our technology in the poster area. Please do come along and chat with us to understand how we can help … Read more
The Medical and Healthcare products Regulatory Agency (MHRA) has licensed mAbsolves novel Fc silencing technology to produce gold standard negative controls for Fc receptor binding assays. The full press release is below.
OmniAb have entered into a licensing agreement for STR. The agreement provides OmniAb with exclusive, sublicensable access to the STR technology for antibodies that have been generated using OmniAb’s antibody discovery platform. For the full press release please see the PDF below.
Our CEO, Geoff Hale, has been confirmed as a keynote speaker at Antibody Engineering and Therapeutics 2023 in Amsterdam. Geoff will be talking about the diversity of antibody formats and modiciations utilised in the clinic and in particular focussing on Fc silencing and the work mAbsolve has done to compare it’s STR silencing mutations with … Read more
Dr. Neil Bodie and colleagues at Paradigm Immunotherapeutics along with collaborators at Kyoto University and Michigan State University have reported on the design of an ultra-high affinity ACE2 variant that has been coupled to an Fc domain incorporating mAbsolve’s STR mutations for silencing and the YTE mutations for half-life extension. It is hoped that this … Read more
Genscript ProBio have licenced mAbsolves first in class solution for abolising antibody effector function to enable their worldwide client base to access the technology in the early research phases of their antibody development projects. The full press release can be accessed below.
On Thursday 22nd September, our CEO, Geoff Hale, will be presenting some of our recent work on the analysis of Fc sequences from antibodies and Fc fusion proteins and the range of variants used for Fc silencing. Abstract: Over the last 40 years, antibodies and antibody-related biologics have probably been the greatest growth area for … Read more
Today our CEO and CSO, Geoff Hale and Ian Wilkinson, have had a new article published in mAbs. The work described in the article started as an internal effort to better understand the number of silenced antibodies in clinical development and the mutations they used. However, the goal of this work broadened out very quickly … Read more
On Saturday 10th September our CSO, Ian Wilkinson, will be giving a webinar to the Chinese Antibody Society on Fc silencing. To sign up click here. Abstract: Antibodies are nature’s pro-drugs, wonderfully evolved to target pathogens and activate immune systems. For certain indications where ADCC or CDC are required this is ideal, however, for many … Read more
On 5 Jul 2022 the UK Intellectual Property Office granted Patent number GB2595299 to mAbsolve. Publication of the patent is expected on 3 Aug 2022. The patent claims cover a range of variants in the immunoglobulin Fc region which effectively eliminate binding to Fc gamma receptors and associated cellular activation, without adverse effects on manufacturability, … Read more